Progress on metronomic chemotherapy for advanced hepatocellular carcinoma
10.3969/j.issn.1000-8179.2017.18.340
- VernacularTitle:节律性化疗在晚期肝细胞肝癌中的应用进展
- Author:
GUO LIEPING
1
Author Information
1. 上海东方肝胆外科医院 上海市201805
- Keywords:
metronomic chemotherapy;
hepatocellular carcinoma;
systemic therapy
- From:
Chinese Journal of Clinical Oncology
2017;44(18):948-952
- CountryChina
- Language:Chinese
-
Abstract:
Primary liver cancer,particularly hepatocellular carcinoma(HCC),is a common type of digestive tumor in China.The majority of HCC patients is diagnosed with advanced stage and thus cannot be treated with surgery and local treatment.Systemic therapy is considered to be the main treatment of advanced HCC.The effect of traditional cytotoxic drug chemotherapy on advanced HCC is not evident.Although sorafenib,a molecular-targeted drug,has survival benefits,this drug is expensive and has low objective effective rate of only 2%-3%. Metronomic chemotherapy has received increasing attention because it targets tumor angiogenesis for the treatment of advanced metastatic cancer.This article aimed to review the progress of metronomic chemotherapy in advanced HCC treatment.
